IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
MWN-AI** Summary
IDEAYA Biosciences, Inc. announced the submission of an investigational new drug (IND) application for IDE574, a promising first-in-class dual inhibitor targeting KAT6 and KAT7 enzymes, which are critical for tumor cell survival in breast and lung cancers. This selective small-molecule inhibitor is designed to disrupt the cancer-promoting activities of these epigenetic modulators while avoiding other similar enzymes, thus offering a potentially more effective treatment option.
The company plans to initiate a Phase 1 dose escalation trial for monotherapy IDE574 in early 2026, marking a significant step in its clinical development. IDE574 has shown promising results in preclinical studies, demonstrating substantial anti-tumor activity and the ability to interfere with specific transcription factors crucial for maintaining tumor lineage identity, particularly in patient-derived xenograft models of lung and breast cancers.
IDEAYA's strategy aligns with its mission to innovate in precision oncology by discovering, developing, and commercializing targeted therapies based on genetic drivers of cancer. Their focus on technologies like synthetic lethality and antibody-drug conjugates further emphasizes their commitment to developing treatments that are tailored to the individual genetic profiles of tumors.
The company also plans to share comprehensive preclinical pharmacologic data and outcomes at a medical conference in the first half of 2026. However, IDEAYA acknowledges the inherent risks and uncertainties associated with drug development and regulatory processes, which could impact the timing and success of their clinical programs.
In summary, IDE574 represents a potential breakthrough in cancer treatment, with IDEAYA positioning itself at the forefront of precision medicine with this innovative drug candidate.
MWN-AI** Analysis
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) has recently made headlines with the submission of an Investigational New Drug (IND) application for IDE574, a promising KAT6/7 dual inhibitor targeting breast and lung cancers. Scheduled to initiate a Phase 1 dose escalation trial in Q1 2026, this potential first-in-class therapy has generated excitement in the oncology sector, providing a compelling case for investors to consider.
The strategic development of IDE574 is timely, given the increasing demand for targeted therapies in oncology. The dual inhibition of KAT6 and KAT7, which are critical in tumor cell survival, sets IDE574 apart from existing treatments. Preclinical studies indicate robust anti-tumor activity, suggesting potential market competitiveness against traditional therapies. Its selectivity in targeting these specific acetyltransferases may lead to fewer side effects, enhancing patient compliance and treatment outcomes.
Investors should note that while the prospect of IDE574 is promising, there are inherent risks in biopharmaceutical development. The timeline for clinical trials can experience delays, regulatory hurdles pose challenges, and the drug's efficacy in a diverse patient population remains to be seen. Therefore, closely monitoring upcoming data presentations and trial results will be crucial. The company plans to unveil preclinical data at a medical conference in H1 2026, a key date for potential investors seeking insights into IDE574’s viability and the company’s execution capabilities.
In conclusion, IDEAYA appears to be well-positioned in the precision oncology landscape with IDE574. However, investors are advised to balance enthusiasm with caution due to the volatility and uncertainty inherent in drug development processes. Keep an eye on the company's developments, as successful outcomes could significantly affect its market trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026
- Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tumor models at a medical conference in 1H 2026
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IDE574, a potential first-in-class KAT6/7 dual inhibitor with high selectivity over related KAT5/8 enzymes. The company is targeting to begin a Phase 1 dose escalation trial of monotherapy IDE574 in the first quarter of 2026.
"IDE574 is a promising potential first-in-class molecule that potently inhibits two tumor-promoting epigenetic modulators, KAT6 and KAT7, while sparing other structurally similar KAT family members. Preclinical studies demonstrate KAT6 and KAT7 collaboratively control lineage-specific tumorigenic transcription factor activity essential for tumor cell proliferation and survival. Dual KAT6/7 inhibition by IDE574 disrupts tumor lineage identity and delivers robust anti-tumor activity in patient-derived lung and breast cancer xenograft models dependent upon lineage-specific transcription factor activity," said Michael White, Ph.D., Chief Scientific Officer of IDEAYA Biosciences.
IDE574 is an equipotent, highly selective, small molecule dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7, both of which have been shown to support cancer cell survival. IND-enabling studies support the potential clinical evaluation of IDE574 monotherapy in patients with hormone receptor-positive breast cancer, lung adenocarcinoma as well as additional opportunities associated with lineage addiction. IDEAYA is targeting to share data from its preclinical work with IDE574 at a medical conference in the first half of 2026.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the potential therapeutic benefits of IDE574, including combination therapies; (ii) the timing of initiating a Phase 1 dose escalation trial of monotherapy IDE574 and (iii) the timing of presenting pre-clinical data at a medical conference for IDE574. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs in early or late stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
SOURCE IDEAYA Biosciences, Inc.
FAQ**
What specific preclinical data regarding the pharmacologic profile and anti-tumor activity of IDE574 is IDEAYA Biosciences Inc. (Nasdaq: IDYA) expecting to present at the medical conference in the first half of 2026?
How does IDEAYA Biosciences Inc. (IDYA) plan to address the potential risks and uncertainties associated with the drug development process for IDE574, particularly regarding regulatory approvals and clinical trials?
In what ways could the dual inhibition of KAT6 and KAT7 by IDE574 offer advantages over existing treatments for patients with hormone receptor-positive breast cancer and lung adenocarcinoma according to IDEAYA Biosciences Inc. (IDYA)?
What financial strategies does IDEAYA Biosciences Inc. (IDYA) have in place to ensure they can fund operations through the clinical development stages of IDE57especially given the potential challenges in manufacturing and regulatory processes?
**MWN-AI FAQ is based on asking OpenAI questions about IDEAYA Biosciences Inc. (NASDAQ: IDYA).
NASDAQ: IDYA
IDYA Trading
0.49% G/L:
$34.96 Last:
186,017 Volume:
$35.27 Open:
